In 2008, the American Society of Clinical Oncology commissioned a report that declared that the partial type of genetic analysis offered by 23andMe had not been clinically proved to be effective in cancer care. Two years later, the US Government Accountability Office concluded after a lengthy investigation that DTC genetic tests provide “misleading” results – a situation that is complicated further by “deceptive marketing.”